Aim of the present investigation was to formulate and evaluate nebivolol hydrochloride transdermal patch. Patches were prepared by 32 factorial design using solvent evaporation technique with different polymers. Propylene glycol was used as plasticizer. 32 factorial design was employed to explore the effects of eudragit RL100 and HPMC K15M (independent variables) on tensile strength, % cumulative drug release at 6 hours and %cumulative drug release at 24 hours (dependent variables). Patches were evaluated for physicochemical characteristics. Drug-polymer compatibility study was determined by fourier transform infrared spectroscopy and differential scanning calorimetry. The results of compatibility studies revealed that there was no interaction between drug and polymers. Results showed drug release in the range of 79.96±0.31-95.89±0.83 and drug content in the range of 92.65±0.21-98.62±0.17. Moisture content and moisture uptake were increased for the patches containing higher amount of HPMC K15M. Patch containing HPMC K15M in higher proportion gives increase in the drug release. It indicates that as the eudragit RL 100 increases the drug release was decreases. On the basis of in-vitro drug release performance, F7 was selected as the optimized formulation. Ex-vivo drug release study carried out for optimized batch and it showed 91.25±0.62% drug release after 24 hours. F7 showed ideal higuchi release kinetics. Skin irritation study for F7 revealed that it was free of irritation. Optimized batch F7 was found to be stable at 40±0.5°C and 75±5% RH during the test period of 1month. From the results, concluded that transdermal patches of nebivolol hydrochloride with desired characteristics could be prepared for prolonged release.
Loading....